Kirby McInerney LLP Advises Esperion Therapeutics, Inc. Investors of Potential Claims
January 13 2016 - 12:12PM
Business Wire
The law firm of Kirby McInerney LLP announced today that a class
action lawsuit has been filed in the United States District Court
for the Eastern District of Michigan against Esperion Therapeutics,
Inc. ("Esperion" or the "Company") (Nasdaq: ESPR) on behalf of all
persons or entities who acquired Esperion securities during the
period from August 18, 2015 through September 28, 2015 (the "Class
Period"). Pursuant to applicable law, investors have until March
14, 2016 to file a motion to be appointed as lead plaintiff in the
investor lawsuit.
The lawsuit alleges that during the Class Period, the Company
falsely portrayed the events of an early August 2015 meeting with
the U.S. Food and Drug Administration (“FDA”). On August 17, 2015,
Esperion stated that during this meeting, the FDA had informed the
Company that it would not need to complete a cardiovascular
outcomes trial to gain approval of its lead product candidate,
ETC-1002.
After the market closed on September 28, 2015, Esperion
disclosed that the FDA had actually encouraged it to “initiate a
cardiovascular outcomes trial promptly.” On this news, the stock
price declined from $35.09 to close at $18.33 on September 29,
2015.
If you acquired Esperion securities during the Class Period and
are interested in learning more about this matter and any rights
you might have with respect to these claims, contact Rona Li at
securitiescases@kmllp.com, or by telephone at (212) 371-6600.
Please bear in mind that some of these rights may be
time-sensitive.
Kirby McInerney LLP is a New York-based plaintiffs' law firm
concentrating in securities, whistleblower, antitrust and consumer
litigation. The firm has specialized in complex litigation,
including securities class actions, for several decades. Kirby
McInerney LLP has repeatedly demonstrated its expertise in this
field, and has been recognized by various courts that have
appointed the firm to major positions in consolidated and
multi-district litigation. The firm's efforts on behalf of
shareholders in securities litigation have resulted in recoveries
totaling billions of dollars, and the firm's achievements and
quality of service have been chronicled in numerous published
decisions. Additional information about the firm or the claims
against Esperion Therapeutics, Inc. can be found at Kirby McInerney
LLP's website: http://www.kmllp.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160113006005/en/
Kirby McInerney LLPRona Li, (212)
371-6600securitiescases@kmllp.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Sep 2024 to Oct 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Oct 2023 to Oct 2024